Addressing the critical demand for ultra-frozen storage
The pharmaceutical and healthcare industries are experiencing unprecedented growth in products requiring stringent ultra-low temperature environments. From innovative vaccines and advanced biotechnological medicines to crucial raw materials and research components, maintaining product integrity at temperatures down to -80°C is paramount.
Movianto, a subsidiary of the French Walden Group and a specialist in healthcare logistics, has proactively responded to this escalating need by developing a robust European network specifically designed for ultra-frozen product logistics. This initiative directly supports businesses in navigating the complexities of modern cold chain management.
Movianto's European network: a blueprint for secure logistics
Movianto’s newly established network offers comprehensive ultra-frozen storage and distribution capabilities across nine strategic European countries: Belgium, the Netherlands, France, Germany, Italy, Spain, Denmark, the Czech Republic, and the United Kingdom. This extensive footprint ensures that pharmaceutical and biotech companies can access reliable, compliant storage solutions across key markets.
Beyond static storage, Movianto also provides specialized transportation services, including the use of custom containers that maintain ultra-low temperatures during transit. For products requiring it, controlled thawing, re-cooling, or re-freezing processes can be managed before final delivery, ensuring seamless cold chain continuity from origin to destination.
Beyond temperature: validation and expertise drive confidence
Movianto's commitment to excellence in ultra-frozen logistics is built on over a decade of specialized experience, significantly bolstered during the COVID-19 pandemic through centralized vaccine storage and distribution in the Netherlands and the UK.
Thomas Creuzberger, CEO of Movianto, emphasizes that success in this field goes far beyond simply installing the right freezers. “It’s not just about installing the right freezers,” he states, “but above all about validating the equipment and processes.” This rigorous approach to validation and adherence to good practices are now standard across all Movianto’s national sites, providing businesses with unparalleled confidence in the integrity of their valuable products.
Why ultra-low temperatures matter for future pharmaceuticals
The significance of ultra-low temperature storage is rapidly increasing, particularly with the acceleration of new vaccine development and advanced therapeutic modalities. In the initial phases of development, crucial stability data for new products is often limited.
Storing these sensitive products at ultra-low temperatures acts as a critical safeguard, guaranteeing their efficacy and potency until comprehensive stability data becomes available. This capability offers pharmaceutical companies a vital risk mitigation strategy, enabling faster product development and market access without compromising quality.
Source: transportmedia.be
